早期治疗药物监测可识别硫嘌呤治疗失败高风险的IBD患者
本研究对多中心前瞻性观察研究进行事后分析,纳入181例启动硫嘌呤治疗的IBD患者,在治疗第7天(T1)检测6-TGN、6-MMPR及比值,随访12周。发现T1时6-MMPR浓度和6-TGN/6-MMPR比值与12周内停药独立相关,并可预测稳态时代谢偏移,但与疗效无关。
要点
- T1时6-MMPR≥3000 pmol/8×10⁸ RBC和6-TGN/6-MMPR≥17与早期停药风险相关。
- T1代谢物浓度可预测第8周稳态代谢偏移(6-MMPR/6-TGN≥11或≥20)。
- 早期TDM有助于识别硫嘌呤治疗失败高风险患者,但不预测疗效。
核心结论
- T1时硫嘌呤代谢物浓度与早期停药和稳态代谢偏移相关,但与疗效无关。
研究设计与样本
- 多中心前瞻性观察研究的事后分析,纳入181例启动硫嘌呤治疗的IBD患者。
主要发现
- 6-MMPR≥3000 pmol/8×10⁸ RBC和6-TGN/6-MMPR≥17时效应最大。
- ADRs发生和疗效与T1代谢物浓度无独立关联。
关键数值与推荐
- 6-MMPR≥3000 pmol/8×10⁸ RBC和6-TGN/6-MMPR≥17与12周内停药风险相关。
- 第8周稳态代谢偏移定义为6-MMPR/6-TGN≥11和≥20。
临床怎么用
- 对启动硫嘌呤治疗的IBD患者,可考虑在第7天监测6-MMPR和6-TGN/6-MMPR比值以识别早期停药高风险者。
局限性
- 本研究为事后分析,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Conventional thiopurines (azathioprine and mercaptopurine) remain standard therapy to maintain steroid sparing remission in inflammatory bowel disease (IBD), but are regularly discontinued due to adverse drug reactions (ADRs). Measurement of the metabolites 6-thioguanine nucleotides (6-TGN), 6-methylmercaptopurine ribonucleotides (6-MMPR) and the 6-MMPR/6-TGN ratio, may predict the development of these ADRs. Our aim was to evaluate whether early thiopurine metabolite measurements were associated with clinical outcomes. METHODS: A post-hoc analysis was conducted of a multicentre, prospective, observational study on thiopurine-induced hepatotoxicity. IBD patients who initiated thiopurine therapy were included and thiopurine metabolite concentrations were assessed after 7 days (±1) (T1). Patients were monitored for 12 weeks to document the occurrence of ADRs, early treatment discontinuation and effectiveness. RESULTS: In total, 181 patients were evaluated. At T1, 6-MMPR concentrations and 6-TGN/6-MMPR ratios were independently related to treatment discontinuation within 12 weeks after correction for sex, age and body mass index (BMI) (P = .034 and .002, respectively). The largest effects were observed for 6-MMPR ≥3000 pmol/8 × 108 RBC and 6-TGN/6-MMPR ratio ≥17. Furthermore, 6-MMPR concentrations and 6-TGN/6-MMPR ratios at T1 were independently related to skewed metabolism at steady state (Week 8, 6-MMPR/-6TGN ratio ≥11 and ≥20) (both P < .001). The occurrence of ADRs and effectiveness were not independently related to T1 thiopurine metabolite concentrations. CONCLUSIONS: Thiopurine metabolite concentrations at T1 were related to early treatment discontinuation and skewed metabolism at steady state, but not to effectiveness, helping to identify patients with a high risk of thiopurine treatment failure.
引用
- Deben DS, Winkens B, van Moorsel SAW, et al. Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment. Br J Clin Pharmacol. 2024. PMID: 39183492. doi:10.1111/bcp.16219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。